CRVS at a glance
Corvus Pharmaceuticals, Inc. (CRVS, SEC CIK 1626971) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Corvus Pharmaceuticals, Inc. (CRVS) shares worth $262.2 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Arcara Jeffrey on November 13, 2026 of 500 shares at $10.71 per share.
- In the last 90 days, CRVS insiders reported 4 open-market purchases ($50K) and 0 open-market sales ($0) on Form 4, a net purchase of $50K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 4 buys · 0 sells
- Net +$50K
- 13F holders
- 24 funds
- $262.2M · −1 vs prior quarter
- Latest 8-K
- Nov 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Clinical-stage biopharma developing targeted immune cell protein inhibitors for immune-mediated diseases, inflammatory diseases, and cancers
- New emphasis: Soquelitinib advanced to Phase 3 trial for relapsed peripheral T cell lymphoma (PTCL) and initiated Phase 2 trial for moderate-to-severe atopic dermatitis
- Strategic shift: Expanded focus on immune and inflammatory diseases from oncology, demonstrated by ITK inhibitor’s novel mechanism rebalancing Th1/Th2/Th17/Treg cells
- Quantitative highlight: Phase 1/1b trial enrolled 75 PTCL patients; Phase 1 atopic dermatitis trial enrolled 72 patients across 4 cohorts with up to 72% EASI score reduction
- Noteworthy fact: FDA granted Fast Track and Orphan Drug designations for soquelitinib in relapsed PTCL; first clinical evidence of ITK inhibitor therapy efficacy in both cancer and inflammatory disease pathways
Risk Factors
- Regulatory risk FDA approval delay for soquelitinib with $21.2M R&D spend in 2025, clinical trial costs up $6.0M YoY
- Macroeconomic risk accumulated deficit $412.3M with net loss $15.3M in 2025, cash runway only through Q2 2028
- Operational risk manufacturing cost increase $4.8M for soquelitinib in 2025, reflecting supply chain cost pressures
- Competitive risk dependence on clinical success of soquelitinib vs oncology market innovations, no approved products yet
- Financial risk reliance on equity funding with $189.4M raised in January 2026 follow-on offering, ATM offering suspended
Management Discussion & Analysis
- Forward-looking statements included but specifics on management outlook or guidance not given
AI summary of the CRVS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales or collaboration revenue
- Net loss $20.3M vs $10.2M YoY, operating margin not applicable due to zero revenue
- Soquelitinib R&D costs $12.5M vs $5.6M, largest program and $6.9M YoY increase
- Cash used in operations $38.0M, cash resources $202.9M after $189.4M equity offering
- Funding expected through Q2 2028, additional capital required amid ongoing clinical-development losses
Risk Factors
- No material changes identified versus the 10-K, with risks largely carried forward
- Liquidity risk: $202.9 million in cash, equivalents and marketable securities expected to fund operations into Q2 2028
- Financial performance risk: $52.0 million net loss and $464.3 million accumulated deficit for nine months ended September 30, 2026
- Regulatory risk: FDA may reject foreign clinical-trial data, potentially requiring additional costly trials
- Operational risk: Third-party manufacturers remain subject to cGMP failures that could suspend trials or delay approvals
- Competitive risk: Larger, better-funded oncology companies may develop more effective therapies faster
AI summary of the CRVS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers Q3 and nine-month 2026 financial results through September 30, 2026
- Includes Corvus Pharmaceuticals’ September 30, 2026 financial position
Item EX-99.1: Item EX-99.1
- Q3 2026 net loss $20.3M, or $0.22 per share, versus $10.2M, or $0.12, in Q3 2025
- R&D expense $17.8M versus $8.5M, reflecting accelerated soquelitinib clinical development
Item 2.02: Results of Operations and Financial Condition
- Press release covers Corvus Pharmaceuticals’ financial results for the three and six months ended June 30, 2026
- Financial position as of June 30, 2026 and a business update announced August 6, 2026
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $18.0M, or $0.19 per share, versus $8.0M loss, reflecting sharply higher development spending
- Research and development expense $16.0M, up from $7.9M, as enrollment advances across Phase 3 PTCL and Phase 2 atopic dermatitis trials
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Ian T. Clark resigning from Corvus Pharmaceuticals’ board effective July 22, 2026
- Departure follows over nine years of board service
AI summaries of CRVS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CRVS
Don't miss the next CRVS filing
- Alerts as it files. A push when CRVS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CRVS, by share count.
- Ask anything. An AI agent that reads every CRVS filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Arcara Jeffrey | Buy | Nov 13, 2026 | 500 | $10.71 |
| Arcara Jeffrey | Buy | Nov 13, 2026 | 503 | $10.37 |
| Arcara Jeffrey | Buy | Nov 12, 2026 | 497 | $11.12 |
| Arcara Jeffrey | Buy | Nov 11, 2026 | 3,000 | $11.46 |
| Moore David Scott | A | Jun 11, 2026 | 15,000 | - |
| Grais Linda | A | Jun 11, 2026 | 15,000 | - |
| Moore David Scott | Buy | Jun 11, 2026 | 21,700 | $11.53 |
| CLARK IAN T | A | Jun 11, 2026 | 15,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$23.4M | -$27.5M | -$43.0M |
| Net Income | -$27.0M | -$62.3M | -$15.3M |
| Balance Sheet | |||
| Total Assets | $45.6M | $68.9M | $71.1M |
| Equity | $38.7M | $32.6M | $61.2M |
| ROE | -69.9% | -191.3% | -25.0% |
| Per Share | |||
| EPS | $-0.56 | $-1.02 | $-0.53 |
| Cash Flow | |||
| Operating CF | -$23.9M | -$25.4M | -$32.8M |
| CapEx | $34K | - | $174K |
Source: XBRL data in Corvus Pharmaceuticals, Inc. (CRVS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CRVS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $262.2M |
| Q2 2026 | 25 | $401.2M |
| Q1 2026 | 25 | $348.4M |
| Q4 2025 | 20 | $141.1M |
| Q3 2025 | 19 | $86.1M |
| Q2 2025 | 19 | $43.1M |
| Q1 2025 | 15 | $23.0M |
| Q4 2024 | 11 | $21.6M |
- Invesco Ltd+46.6K (+112%)
- Vanguard Capital Management LLC+26.4K (+1%)
- Citigroup+23.9K (+21%)
- D.E. Shaw & Co+23.7K (+18%)
- Northern Trust+7.9K (+1%)
- State Street Corp−1.14M (-26%)
- Goldman Sachs Group−929.3K (-59%)
- T. Rowe Price Group−731.4K (-19%)
- Morgan Stanley−552.0K (-41%)
- Millennium Management−442.3K (-42%)
- FMR LLC (Fidelity)−2.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 158 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CRVS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 13, 2026 | - | - | - |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 22, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | May 20, 2026 | - | - | |
| SC 13G | May 15, 2026 | - | - | |
| 8-K | May 14, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 27, 2026 | - | - | - |
| 8-K | Apr 23, 2026 | - | Analysis | - |
| 8-K | Mar 13, 2026 | - | Analysis | - |
| 10-K | Mar 12, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Mar 12, 2026 | - | Analysis | - |
| SC 13G | Jan 30, 2026 | - | - | |
| 4 | Jan 30, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CRVS SEC filings: frequently asked questions
Are CRVS insiders buying or selling?
In the last 90 days, Corvus Pharmaceuticals, Inc. (CRVS) officers, directors and 10% owners reported 4 open-market purchases worth $50,475 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CRVS stock?
As of September 30, 2026, the largest Corvus Pharmaceuticals, Inc. (CRVS) holders among the 13F filers tracked by SignalX were BlackRock ($81.8 million), State Street Corp ($38.4 million), Vanguard Capital Management LLC ($38.2 million), T. Rowe Price Group ($35.2 million), Morgan Stanley ($9.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the main risks in CRVS's latest 10-K?
In the 10-K filed March 12, 2026, Corvus Pharmaceuticals, Inc. (CRVS) flagged: Regulatory risk FDA approval delay for soquelitinib with $21.2M R&D spend in 2025, clinical trial costs up $6.0M YoY. Macroeconomic risk accumulated deficit $412.3M with net loss $15.3M in 2025, cash runway only through Q2 2028. (AI summary of the Risk Factors section.)
What did CRVS report in its latest 8-K?
Corvus Pharmaceuticals, Inc. (CRVS) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers Q3 and nine-month 2026 financial results through September 30, 2026.
What are the latest CRVS SEC filings?
Corvus Pharmaceuticals, Inc. (CRVS) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.
What is CRVS's SEC CIK number?
Corvus Pharmaceuticals, Inc. (CRVS)'s SEC Central Index Key (CIK) is 1626971. EDGAR lists every CRVS filing under that number.
Ask anything about CRVS
The research agent reads CRVS's filings, financials, insider trades and 13F holders, then answers with sources.